Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Tuberculosis in the United States 2021 Slide Set										Related Pages
										Return to Main Menu
NOTE: The slide set is in the public domain. You may reproduce these slides without permission; however it is requested that you include an attribution that the materials were developed by CDC (e.g., “Source: CDC” or “Slides developed by CDC”). No substantive changes should be made to the content.Tuberculosis in the United States—National Tuberculosis Surveillance System, Highlights from 2021.Slide - 1This graph shows the annual number of TB cases in the United States for each year during 1982–2021Slide - 2During 2021, the United States reported 7,882 TB cases, an incidence rate of 2.4 cases per 100,000 persons.Slide - 3The top graph shows incidence rates (cases per 100,000 persons) since 2010.Slide - 4The National Vital Statistics System (NVSS) reported 600 TB-related deaths (0.2 deaths per 100,000 persons)Slide - 5Among U.S. states, close to half (49.9%) of TB cases continue to be reported from 4 states.Slide - 6Nine states and the District of Columbia had incidence rates higher than the national rate of 2.4 cases per 100,000 persons.Slide - 7This map shows each state shaded based on two scales, one representing TB case counts and one representing incidence rates.Slide - 8TB Incidence Rates* by U.S.-Affiliated Pacific Islands and Hawaii, 2020Slide - 9Among the U.S.-Affiliated Pacific Islands, incidence rates.Slide - 10The distribution of the origin of birth for persons with TB remained similar in 2021 to previous years.Slide - 11Incidence rates for U.S.-born persons are shown in the left figure in purple, and incidence rates for non-U.S.–born persons.Slide - 12The TB incidence rate among non-U.S.–born persons of 12.5 per 100,000 persons was 16 times the rate of 0.8 per 100,000.Slide - 13In 2021, five countries of birth accounted for 54% of countries of birth origin among non-U.S.–born persons.Slide - 14The countries of birth with the highest U.S. incidence rates of TB disease.Slide - 15This slide shows the percentage of TB cases among the non-U.S.–born by number of years.Slide - 16This graph shows overall TB case counts in the past decade by race/ethnicity.Slide - 17This 100% stacked bar chart shows percentage distributions over time by race/ethnicity.Slide - 18This bar chart shows the percentage of TB cases by race/ethnicity for 2021.Slide - 19TB incidence rates (number of cases per 100,000 persons) vary by race/ethnicity groups.Slide - 20The number of TB cases reported among U.S.-born persons has declined since 2011.Slide - 21In 2021, among U.S.-born persons, Native Hawaiian or Other Pacific Islander persons had the highest incidence rate.Slide - 22The number of TB cases reported among non-U.S.–born persons increased from 2020 (n=5,145) to 2021 (n=5,626).Slide - 23In 2021, among non-U.S.–born persons, persons who identify with more than one race had the highest incidence rate.Slide - 24These figures show TB incidence rates by race/ethnicity among non-U.S.–born persons and U.S.-born persons.Slide - 25The distribution of race/ethnicity among persons with TB disease continued to differ markedly by origin of birth in 2021.Slide - 26This slide shows TB incidence rates (cases per 100,000 persons) by race/ethnicity among non-U.S.–born persons compared with U.S.-born persons in 2021.Slide - 27The distribution of TB cases by age group in 2021 remained similar to past years.Slide - 28TB incidence rates are higher among adults than among children, and among persons 15 years and older, the incidence rates.Slide - 29The change in number of cases among U.S.-born persons by age from 1994 to 2021.Slide - 30Since 1994, each age group among U.S.-born persons has experienced a 72% or greater decline in incidence rate.Slide - 31The percentage of TB cases by age group among non-U.S.–born persons remained relatively the same from 2020 to 2021.Slide - 32From 1994 through 2020, each age group among non-U.S.–born persons has experienced a 50% or greater decline in incidence.Slide - 33This slide examines the percentage of TB cases by birth decade cohort.Slide - 34This slide examines the percentage of TB cases by birth decade cohort.Slide - 35Males continued to represent the majority (61.3%) of persons with TB disease overall.Slide - 36In contrast to overall U.S. TB cases, for which over two-thirds of cases were among non-U.S.–born persons.Slide - 37In 2021, the majority (80%) of children less than 15 years old with TB disease were U.S.-born, however, the incidence rate.Slide - 38In 2021, most TB cases continued to be verified by positive culture at 79.2% (n=6,244), with other laboratory-confirmation methods.Slide - 39Pediatric TB Cases by Age Group, United States, 1993–2020Slide - 40The vast majority of TB cases had pulmonary involvement (78.8%).Slide - 41Since the early 2000s, the percentage of patients started on the standard initial four-drug regimen.Slide - 42Of TB patients who were on therapy in 2021, 83.2% started on isoniazid, rifampin, pyrazinamide, and ethambutol.Slide - 43The percentage of people with TB disease receiving at least a portion of their medication by directly observed therapy.Slide - 44During 2019, the most recent year for which treatment completion data are available.Slide - 45Percentage of TB Cases* by Completion of TB Therapy,United States, 1993–2019†Slide - 46Successful therapy completion for people with TB disease is a major performance indicator for TB programs.Slide - 47TB Cases Resistant to Isoniazid* by Origin of Birth,† United States, 1993–2021Slide - 48Number and Percentage of Multidrug-Resistant (MDR)* TB Cases by History of TB, United States, 1993–2021Slide - 49Percentage of HIV Coinfection by Age Among Persons with TB,* United States, 2011–2021Slide - 50Percentage of Selected Risk Factors Among Persons with TB by Origin of Birth,* United States, 2021Slide - 51Percentage of Social and Behavioral Risk Factors Among Persons Aged ≥15 Years with TB, United States, 2021Slide - 52Number and Percentage of Correctional Facility* Residents Among Persons Aged ≥15 Years with TB, United States, 1993–2021Slide - 53TB Cases Among Correctional Facility Residents Aged ≥15 Years by Type of Facility, United States, 1993–2021Slide - 54TB Cases Among Correctional Facility Residents Aged ≥15 Years by Type of Facility, United States, 2021Slide - 55Percentage of TB Cases by Primary Occupation* Among Persons Aged ≥15 Years, United States, 2021 (N=5,795)Slide - 56Percentage of TB Cases by Statusand Cause of Death, United States, 2019* (N=8,898)Slide - 57National TB Genotyping Surveillance Coverage,* United States, 2004–2021Slide - 58National TB Genotyping Surveillance Coverage,* United States, 2004–2021Slide - 59Definitions for TB Genotyping in the United StatesSlide - 60Number of County-based TB Genotype Clusters* by Cluster Size, United States, 2019–2021Slide - 61TB Genotype Clusters by TB GIMS* Alert Levels,† United States, 2019–2021 (N=1,241)Slide - 62Genotyped TB Cases Estimated to be Attributed to Recent Transmission, United States, 2020–2021 (N=11,404)Slide - 63Genotyped Cases Estimated to be Attributed to Limited and Extensive Recent Transmission,* United States, 2018–2021Slide - 64Percentages of TB Cases Estimated to be Attributed and Not Attributed to Recent Transmission* by Origin of Birth,† 2020–2021Slide - 65Percentage of TB Cases Estimated to be Attributed to Recent Transmission* by Race/Ethnicity,† United States, 2018–2021Slide - 66Percentage of TB Cases Estimated to be Attributed to Extensive Recent Transmission* by Race/Ethnicity,† United StatesSlide - 67For more information, please contact Division of Tuberculosis Elimination at http://www.cdc.gov/tb/.Slide - 68National Tuberculosis Surveillance System Highlights from 2021This slide series was developed as an accompaniment to the document Reported Tuberculosis in the United States, 2021
Download complete set (68 slides) [PPT – 8 MB]
PDF Version [PDF – 2 MB]
Slide Set Narrative [PDF – 344 KB]Related Links
Archived Surveillance Slide Sets
							
					
							Last Reviewed:  November 29, 2022						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue